The US Food and Drug Administration is trying to simplify the terminology it uses to describe remote site and data assessments.
The intent is to clear up stakeholder confusion resulting from the use of multiple abbreviations, all containing the letter “R”, to describe various types of remote approaches, Sean Kassim, director of the Center for Drug Evaluation and Research’s Office of Study Integrity and Surveillance (OSIS), said at a good clinical practices workshop